Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

NCT05943496 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Acalabrutinib
PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Bone Marrow Biopsy
PROCEDURE: Computed Tomography
PROCEDURE: Echocardiography
BIOLOGICAL: Obinutuzumab
OTHER: Questionnaire Administration
BIOLOGICAL: Tafasitamab

Sponsor

OHSU Knight Cancer Institute

Collaborators

[object Object]
[object Object]